FDA approves Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn), the first treatment for Ebola virus

Inmazeb, a mixture of three monoclonal antibodies, targets glycoprotein that is on surface of Ebola virus to block its attachment and entry. It was evaluated in 382 adults and children in the PALM trial conducted in Democratic Republic of the Congo during outbreak in 2018-2019.

Source:

Biospace Inc.